Gan & Lee Pharmaceuticals.

This study is for people who already completed a year-long weight loss trial with the GZR18 injection. It tests whether switching to a shot every 4 weeks for 24 weeks can safely maintain or further reduce body weight. About 500 adults with overweight or obesity will take part, wh…

This study tests a new injectable drug called GZR18 against the well-known weight-loss medication Wegovy (semaglutide) in 420 adults who are obese or overweight. The main goal is to see how much weight participants lose after 52 weeks of treatment. The trial is currently recruiti…

This study tests a new insulin, GZR4, against another long-acting insulin (Icodec) in 300 adults with type 2 diabetes who already use basal insulin. The goal is to see which one controls blood sugar better and causes fewer side effects like low blood sugar. Participants may also …

This study looks at how the drug GZR18 behaves in people with different levels of kidney function, from normal to severe impairment. About 32 overweight or obese adults will receive a single dose and be monitored for up to 50 days. The goal is to find the right dose for patients …